

SUPPLEMENTAL INFORMATION AND DISCLOSURE STATEMENT

Period Ending March 31, 2022
NDT PHARMACEUTICALS, INC.
Trading Symbol: NDTP

OTC Pink Supplemental Disclosure – Non-Shell Status

NDT Pharmaceuticals, Inc. (the “Company”) was previously as shell company, and its annual report for the year ended December 31, 2020, posted on OTCMarkets.com via OTCIQ on September 27, 2021, indicated that the issuer had ceased to be a shell company during that reporting period.

As disclosed in that annual report, and in the Company’s subsequent reports:


Prior company mineral operations were abandoned in 2008, the Company was revived with the State of Nevada in September of 2019, and *in* July of 2020 (with an effective date of January 1, 2020), the Company acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University’s NPC technology described below from Compelling Competitive Advantage, LLC (“CCA”), a Delaware limited liability company which is controlled by the Company’s then-CEO and Director, James Hovis, in consideration of the Company’s issuance of 28,000 shares of Series B Preferred Stock of the Company to CCA. CCA assigned all its rights, title and interests in CCA’s Sponsored Research Agreement with the Trustees of the University of Pennsylvania, and any related trade secrets, technology, know-how, formulations, procedures and/or methodologies (the “Intellectual Property”) to the Company.

The Intellectual Property includes a versatile and widely applicable biotechnology asset base, including the Nanoscale Particle Complex (“NPC”) technology, which represents the leading edge of phospholipid-based nano-encapsulation delivery systems (less than 100 nanometers in diameter; mean diameter of 40 nanometers in current liquid product samples with the capability to engineer significantly smaller nanocarrier particles) that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. Encapsulated actives are protected from destruction in the highly acidic environment of the stomach until they reach the small intestine, providing for much greater absorption of payloads. The instant delivery aspect (an Oral IV) is designed to provide the consumer with rapid effect upon consumption of the product containing the NPC technology. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue branded by the Company as “Cell Armor.”

As disclosed above, the Company ceased to be a shell company on July 30, 2020, when it acquired all rights under the Sponsored Research Agreement with the University of Pennsylvania from CCA.

As the Company is now developing the NPC technology and has the contract rights described above, it is no longer a shell company as it has non-nominal operations and intangible non-cash assets (even though under GAAP, it cannot yet attribute a significant value to those assets).

Dated: July 14, 2022

A handwritten signature in black ink, appearing to read "Joseph C. Passalaqua". The signature is fluid and cursive, with the first name "Joseph" and last name "Passalaqua" clearly legible.

/s/ Joseph C. Passalaqua –
Director/President/CFO/Secretary